InvestorsHub Logo
Boards
News
Market Data
Markets
Discover
Discover
AI Subscribe Login/Register account icon
S&P 500
5,711.75
(
0.16%
)
US TECH 100
19,306.80
(
0.05%
)
Dow Jones
42,103.01
(
0.09%
)
Brent Oil
73.27
(
-0.84%
)
Bitcoin
63,271.93
(
-0.55%
)
Post# of 316942
Next 10
Reply Private New
Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next

cintrix

Send PM Follow Ignore
Followers 363
Posts 113992
Boards Moderated 5
Alias Born 12/28/2000

cintrix

Member Level

Re: None

Friday, 12/14/2018 9:57:04 AM

Friday, December 14, 2018 9:57:04 AM

Post# of 316942
ADXS down 34% Advaxis disclosed in a filing with the US Securities and Exchange Commission that Amgen recently provided notice to terminate the companies' agreement covering development of the experimental cancer immunotherapy ADXS-NEO. The deal, which was potentially worth more than $500 million to Advaxis, will end on February 8 next year.
Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Last Read Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next
Join InvestorsHub

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.

Sign Up